| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 14 | 62.7x | 17.3x | Bottom tier | |
Growth | 48 | -0.4% | 7.1% | Around median | |
Quality | 77 | 8.1% | 4.5% | Top tier | |
Safety | 94 | 0.1x | 2.6x | Top tier | |
Capital Return | 54 | 0.44% | 0.06% | Around median | |
Momentum | 90 | 22.4% | -1.6% | Top tier | |
Sentiment | 81 | 9 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
84% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 5.00% as of 2026-10-23. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Bio-Techne provides tools and technologies that serve the life sciences research continuum from early discovery through translational research, manufacturing, and diagnostics. Its portfolio includes more than 6,000 proteins and 400,000 types of antibodies, the Ella and Maurice protein analysis platforms, COMET and RNAscope spatial biology products, as well as GMP-compliant reagents and clinical control and precision diagnostics solutions. In April 2026, the company consolidated ten brands into three brands: R&D Systems, Bio-Techne Spatial Biology, and Bio-Techne Diagnostics, to simplify customer access to its products.
In Q3 of fiscal 2026, revenue was $311.4 million, down 2% organically and on a reported basis, while gross profit was $208.3 million, net income was $51.0 million, and GAAP earnings per share were $0.32. This equates to a reported gross margin of approximately 66.9% and a net income margin of approximately 16.4%, while adjusted gross margin was 70.4% and adjusted operating margin was 34.2%. Net income improved from $38.0 million in Q2 of fiscal 2026, alongside an increase in revenue from $295.9 million.
The Protein Sciences segment represented approximately $226.2 million, or about 72.6% of Q3 fiscal 2026 revenue, and its organic revenue declined 4%. The Diagnostics and Spatial Biology segment recorded sales of $85.6 million, or about 27.5% of revenue, with 3% organic growth despite a 4% decline in reported revenue due to the impact of the Exosome Diagnostics divestiture. For the twelve months ended in 2026, revenue was $1.2 billion, gross profit was $786.5 million, and net income was $109.6 million.
The average analyst price target is $65.78, with a wide range from $50 to $73 and a Neutral consensus, reflecting the market's balance between the strength of COMET and cell therapy and organic revenue contraction and weakness among emerging biotechnology companies. The average target is below the 52-week high of $72.62, while the highest target of $73 nearly matches that high; the available information does not present a reliable earnings multiple, so achieving a recovery in growth and margins remains essential to justify the upper end of the target range.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Bio-Techne sells reagents, proteins, antibodies, protein analysis and spatial biology instruments, and precision diagnostics solutions. Its portfolio includes more than 6,000 proteins and 400,000 types of antibodies, alongside Ella, Maurice, COMET, and RNAscope. In Q3 of fiscal 2026, Protein Sciences generated revenue of $226.2 million, compared with $85.6 million for Diagnostics and Spatial Biology. In April 2026, the company consolidated its portfolio under R&D Systems, Bio-Techne Spatial Biology, and Bio-Techne Diagnostics.
Revenue was $311.4 million and declined 2% organically and on a reported basis in Q3 of fiscal 2026. The timing of orders from two large cell therapy customers that received FDA Fast Track designation created a three-percentage-point drag, and the shift of a large commercial supply order to the previous quarter added another percentage point. Excluding these two factors, underlying organic growth was 2%. Spending by emerging biotechnology companies also declined at a high-single-digit rate, limiting the impact of growth among large pharmaceutical customers.
Automated analysis for informational purposes only — not investment advice.
COMET is a spatial biology multiomics platform, and its revenue grew by more than 65% in Q3 of fiscal 2026. The company installed its first COMET system in China during the period and ended the quarter with a record backlog. This contributed to mid-teens growth in the spatial biology portfolio, alongside high-single-digit growth in RNAscope. Providence Health and Microsoft also used data generated through COMET within GigaTIME to transform conventional tissue images into three-dimensional virtual histological representations.
Biotechnology funding estimates rose by more than 90% in Q2 of fiscal 2026 and by more than 50% in Q3 of fiscal 2026. Management's experience indicates that the lag between funding and customer spending typically ranges from one quarter to four quarters, with an average of two to three quarters. Nevertheless, the company assumed in its outlook that emerging biotechnology performance would remain at Q3 fiscal 2026 levels during the following quarter. Management estimated that a meaningful improvement would likely begin in the first half of fiscal 2027, while timing remained uncertain.
Bio-Techne ended Q3 of fiscal 2026 with $209.8 million in cash and $200 million in bank debt, after reducing debt by $60 million during the quarter. It generated $86.7 million in operating cash flow, against $9.1 million in net capital expenditures, and returned $12.5 million to shareholders through dividends. On August 13, 2026, the company announced that it was raising its quarterly dividend from $0.08 to $0.65 per share, an increase of 712.5%. The report stated that the payout ratio was 15.4% and the dividend yield was 3.6%.
The most important indicator is the conversion of biotechnology funding into actual orders, following a high-single-digit decline in revenue from emerging customers in Q3 of fiscal 2026. The continuation of COMET growth, which exceeded 65%, and GMP protein growth, which approached 50% after excluding two large customers, should be monitored. The cell therapy portfolio includes 85 clinical programs, including 18 in Phase II and six in Phase III, providing a measure of customer progress. A return of protein analysis to double-digit growth and a recovery in margins after adjusted operating margin declined to 34.2% will also be important signs that the recovery is broadening.